Rice Hall James & Associates LLC Boosts Stock Position in Evolus, Inc. $EOLS

Rice Hall James & Associates LLC increased its holdings in Evolus, Inc. (NASDAQ:EOLS) by 8.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,254,819 shares of the company’s stock after purchasing an additional 101,375 shares during the period. Rice Hall James & Associates LLC owned approximately 1.91% of Evolus worth $5,157,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. State of Wyoming grew its stake in shares of Evolus by 226.6% in the 1st quarter. State of Wyoming now owns 31,016 shares of the company’s stock worth $127,000 after buying an additional 21,519 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Evolus by 3.9% during the 1st quarter. Bank of New York Mellon Corp now owns 143,164 shares of the company’s stock valued at $588,000 after buying an additional 5,367 shares in the last quarter. Chicago Partners Investment Group LLC purchased a new stake in shares of Evolus during the 1st quarter valued at about $79,000. Hsbc Holdings PLC bought a new position in shares of Evolus in the 1st quarter valued at about $142,000. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of Evolus by 121.4% in the 1st quarter. Assenagon Asset Management S.A. now owns 598,145 shares of the company’s stock valued at $2,458,000 after acquiring an additional 327,926 shares during the last quarter. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Stock Down 0.2%

NASDAQ EOLS opened at $5.98 on Friday. Evolus, Inc. has a 52 week low of $3.86 and a 52 week high of $9.72. The firm has a market capitalization of $393.84 million, a price-to-earnings ratio of -8.93 and a beta of 1.32. The company has a fifty day moving average of $6.50 and a two-hundred day moving average of $5.48.

Evolus (NASDAQ:EOLS) last announced its earnings results on Monday, May 4th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The firm had revenue of $73.14 million for the quarter, compared to analyst estimates of $72.52 million. During the same quarter in the prior year, the company posted ($0.30) earnings per share. Equities research analysts anticipate that Evolus, Inc. will post -0.38 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on EOLS shares. BTIG Research reissued a “buy” rating and set a $13.00 price objective on shares of Evolus in a research note on Wednesday, June 17th. Weiss Ratings raised Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.00.

Evolus Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.